Propanc Biopharma, Inc. financial data

Symbol
PPCB on OTC
Industry
Pharmaceutical Preparations
Location
302/6 Butler Street, Camberwell, Victoria, Australia
State of incorporation
DE
Fiscal year end
June 30
Former names
Propanc Health Group Corp (to 4/5/2017)
Latest financial report
10-Q - Q3 2024 - Nov 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.76 % -30.9%
Debt-to-equity -103 % +1.33%
Return On Equity 48.2 % -39.8%
Return On Assets -1.76K % +9.65%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 688M shares +4538%
Common Stock, Shares, Outstanding 688M shares +4538%
Entity Public Float 425K USD -42.5%
Common Stock, Value, Issued 688K USD +4538%
Weighted Average Number of Shares Outstanding, Basic 591M shares +5277%
Weighted Average Number of Shares Outstanding, Diluted 591M shares +5277%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 294K USD +80.3%
General and Administrative Expense 1.08M USD -24.4%
Operating Income (Loss) -1.41M USD +13%
Nonoperating Income (Expense) -543K USD +39.8%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -1.95M USD +22.6%
Income Tax Expense (Benefit) -275 USD +84%
Net Income (Loss) Attributable to Parent -1.82M USD +23.8%
Earnings Per Share, Basic 0.02 USD/shares -93.1%
Earnings Per Share, Diluted 0.02 USD/shares -93.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Assets, Current 21.5K USD -85.2%
Property, Plant and Equipment, Net 50 USD -95.4%
Assets 63.6K USD -64.7%
Accounts Payable, Current 1.24M USD +14.5%
Employee-related Liabilities, Current 678K USD +17.1%
Liabilities, Current 4.1M USD +30.9%
Liabilities 4.17M USD +31.6%
Accumulated Other Comprehensive Income (Loss), Net of Tax 1.17M USD -14.5%
Retained Earnings (Accumulated Deficit) -67.1M USD -2.88%
Stockholders' Equity Attributable to Parent -4.11M USD -37.4%
Liabilities and Equity 63.6K USD -64.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -236K USD +29.4%
Net Cash Provided by (Used in) Financing Activities 216K USD -38.4%
Common Stock, Shares Authorized 10B shares 0%
Common Stock, Shares, Issued 688M shares +4538%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -11.8K USD -245%
Interest Paid, Excluding Capitalized Interest, Operating Activities 2.61K USD -3.94%
Deferred Tax Assets, Valuation Allowance 11.5M USD +2.75%
Deferred Tax Assets, Gross 12.1M USD +2.51%
Depreciation 297 USD -82.2%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -2.07M USD +20.5%
Lessee, Operating Lease, Liability, to be Paid 14.2K USD -58.7%
Property, Plant and Equipment, Gross 26.5K USD +7.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 20K USD -19.7%
Lessee, Operating Lease, Liability, to be Paid, Year One 20.1K USD -16.3%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.78K USD -65.6%
Deferred Tax Assets, Operating Loss Carryforwards 9.08M USD +1.84%
Preferred Stock, Shares Authorized 1.5M shares 0%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 61.1M USD +0.46%
Deferred Tax Assets, Net of Valuation Allowance 11.5M USD +2.75%
Interest Expense 690K USD +29.7%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%